Related Experiment Video
Updated: Aug 13, 2026
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
DDX3X dynamics, glioblastoma's genetic landscape, therapeutic advances, and autophagic interplay
Arpit Sharma1, Shruti S Raut1, Alok Shukla1
1Biomolecular Engineering Laboratory, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, 221005, India.
Abstract:
Glioblastoma is one of the most aggressive and deadly forms of cancer, posing significant challenges for the medical community. This review focuses on key aspects of Glioblastoma, including its genetic differences between primary and secondary types. Temozolomide is a major first-line treatment for Glioblastoma, and this article explores its development, how it works, and the issue of resistance that limits its effectiveness, prompting the need for new treatment strategies. Gene expression profiling has greatly advanced cancer research by revealing the molecular mechanisms of tumors, which is essential for creating targeted therapies for Glioblastoma. One important protein in this context is DDX3X, which plays various roles in cancer, sometimes promoting it or otherwise suppressing it. Additionally, autophagy, a process that maintains cellular balance, has complex implications in cancer treatment. Understanding autophagy helps to identify resistance mechanisms and potential treatments, with Chloroquine showing promise in treating Glioblastoma. This review covers the interplay between Glioblastoma, DDX3X, and autophagy, highlighting the challenges and potential strategies in treating this severe disease.
Insights
Glioblastoma treatment faces challenges due to drug resistance. This review explores Glioblastoma genetics, Temozolomide resistance, DDX3X protein roles, and autophagy, highlighting potential therapeutic strategies like Chloroquine.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma is an aggressive brain cancer with poor prognosis.
- Understanding Glioblastoma's genetic heterogeneity (primary vs. secondary) is crucial.
- Current treatments like Temozolomide face significant resistance issues.
Purpose of the Study:
- To review key aspects of Glioblastoma, including genetics and treatment resistance.
- To explore the role of DDX3X protein in Glioblastoma development and progression.
- To examine the complex role of autophagy in Glioblastoma and its therapeutic implications.
Main Methods:
- Literature review of Glioblastoma research.
- Analysis of gene expression profiling data.
- Investigation of molecular mechanisms involving DDX3X and autophagy.
Main Results:
- Glioblastoma exhibits genetic differences between primary and secondary types.
- Temozolomide resistance is a major limitation in Glioblastoma treatment.
- DDX3X has dual roles (oncogenic/tumor-suppressive) in cancer.
- Autophagy modulation, potentially with Chloroquine, shows promise for Glioblastoma therapy.
Conclusions:
- Targeted therapies are needed for Glioblastoma, informed by molecular profiling.
- Understanding DDX3X and autophagy interplay is key to overcoming treatment resistance.
- Chloroquine represents a potential therapeutic avenue for Glioblastoma treatment.
Related Concept Videos
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...